QQQ   305.05 (-0.10%)
AAPL   155.05 (+0.03%)
MSFT   278.25 (-0.42%)
META   197.70 (+1.07%)
GOOGL   100.70 (-0.91%)
AMZN   98.61 (-0.34%)
TSLA   178.25 (-1.04%)
NVDA   257.70 (+0.17%)
NIO   8.15 (-1.33%)
BABA   80.54 (-1.38%)
AMD   97.70 (-0.14%)
T   18.14 (+0.06%)
F   11.35 (+0.44%)
MU   56.70 (+0.07%)
CGC   2.01 (+0.50%)
GE   90.52 (+0.25%)
DIS   93.40 (+0.21%)
AMC   4.20 (+0.48%)
PFE   40.15 (+0.12%)
PYPL   73.17 (+0.25%)
NFLX   303.01 (-0.16%)
QQQ   305.05 (-0.10%)
AAPL   155.05 (+0.03%)
MSFT   278.25 (-0.42%)
META   197.70 (+1.07%)
GOOGL   100.70 (-0.91%)
AMZN   98.61 (-0.34%)
TSLA   178.25 (-1.04%)
NVDA   257.70 (+0.17%)
NIO   8.15 (-1.33%)
BABA   80.54 (-1.38%)
AMD   97.70 (-0.14%)
T   18.14 (+0.06%)
F   11.35 (+0.44%)
MU   56.70 (+0.07%)
CGC   2.01 (+0.50%)
GE   90.52 (+0.25%)
DIS   93.40 (+0.21%)
AMC   4.20 (+0.48%)
PFE   40.15 (+0.12%)
PYPL   73.17 (+0.25%)
NFLX   303.01 (-0.16%)
QQQ   305.05 (-0.10%)
AAPL   155.05 (+0.03%)
MSFT   278.25 (-0.42%)
META   197.70 (+1.07%)
GOOGL   100.70 (-0.91%)
AMZN   98.61 (-0.34%)
TSLA   178.25 (-1.04%)
NVDA   257.70 (+0.17%)
NIO   8.15 (-1.33%)
BABA   80.54 (-1.38%)
AMD   97.70 (-0.14%)
T   18.14 (+0.06%)
F   11.35 (+0.44%)
MU   56.70 (+0.07%)
CGC   2.01 (+0.50%)
GE   90.52 (+0.25%)
DIS   93.40 (+0.21%)
AMC   4.20 (+0.48%)
PFE   40.15 (+0.12%)
PYPL   73.17 (+0.25%)
NFLX   303.01 (-0.16%)
QQQ   305.05 (-0.10%)
AAPL   155.05 (+0.03%)
MSFT   278.25 (-0.42%)
META   197.70 (+1.07%)
GOOGL   100.70 (-0.91%)
AMZN   98.61 (-0.34%)
TSLA   178.25 (-1.04%)
NVDA   257.70 (+0.17%)
NIO   8.15 (-1.33%)
BABA   80.54 (-1.38%)
AMD   97.70 (-0.14%)
T   18.14 (+0.06%)
F   11.35 (+0.44%)
MU   56.70 (+0.07%)
CGC   2.01 (+0.50%)
GE   90.52 (+0.25%)
DIS   93.40 (+0.21%)
AMC   4.20 (+0.48%)
PFE   40.15 (+0.12%)
PYPL   73.17 (+0.25%)
NFLX   303.01 (-0.16%)
NASDAQ:AEZS

Aeterna Zentaris - AEZS Stock Forecast, Price & News

$2.71
-0.04 (-1.45%)
(As of 03/17/2023 06:55 PM ET)
Add
Compare
Today's Range
$2.70
$2.74
50-Day Range
$2.61
$3.89
52-Week Range
$2.54
$9.75
Volume
4,500 shs
Average Volume
13,210 shs
Market Capitalization
$13.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.50

Aeterna Zentaris MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,283.8% Upside
$37.50 Price Target
Short Interest
Bearish
1.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Aeterna Zentaris in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.04) to ($3.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

790th out of 983 stocks

Pharmaceutical Preparations Industry

377th out of 480 stocks


AEZS stock logo

About Aeterna Zentaris (NASDAQ:AEZS) Stock

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company, which engages in the development of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

AEZS Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
AEZS Aeterna Zentaris Inc.
See More Headlines
Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

AEZS Company Calendar

Last Earnings
11/04/2021
Today
3/20/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AEZS
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.50
High Stock Price Forecast
$37.50
Low Stock Price Forecast
$37.50
Forecasted Upside/Downside
+1,283.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-8,370,000.00
Pretax Margin
-319.87%

Debt

Sales & Book Value

Annual Sales
$5.26 million
Book Value
$10.91 per share

Miscellaneous

Free Float
4,851,000
Market Cap
$13.17 million
Optionable
Optionable
Beta
1.43

Social Links


Key Executives

  • Klaus Wolfgang Paulini
    President, Chief Executive Officer & Director
  • Giuliano La Fratta
    Chief Financial Officer & Senior Vice President
  • Michael Teifel
    Chief Scientific Officer & Senior Vice President
  • Nicola Ammer
    Chief Medical Officer & Senior Vice President
  • Matthias Gerlach
    Vice President-Manufacturing & Supply Chain













AEZS Stock - Frequently Asked Questions

Should I buy or sell Aeterna Zentaris stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings
or view top-rated stocks.

What is Aeterna Zentaris' stock price forecast for 2023?

1 equities research analysts have issued 1-year target prices for Aeterna Zentaris' shares. Their AEZS share price forecasts range from $37.50 to $37.50. On average, they predict the company's share price to reach $37.50 in the next twelve months. This suggests a possible upside of 1,283.8% from the stock's current price.
View analysts price targets for AEZS
or view top-rated stocks among Wall Street analysts.

How have AEZS shares performed in 2023?

Aeterna Zentaris' stock was trading at $3.18 at the beginning of the year. Since then, AEZS stock has decreased by 14.8% and is now trading at $2.71.
View the best growth stocks for 2023 here
.

Are investors shorting Aeterna Zentaris?

Aeterna Zentaris saw a increase in short interest in February. As of February 28th, there was short interest totaling 87,000 shares, an increase of 7.0% from the February 13th total of 81,300 shares. Based on an average daily trading volume, of 15,700 shares, the short-interest ratio is presently 5.5 days. Approximately 1.8% of the shares of the stock are short sold.
View Aeterna Zentaris' Short Interest
.

When is Aeterna Zentaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our AEZS earnings forecast
.

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.25. The biopharmaceutical company earned $0.60 million during the quarter, compared to the consensus estimate of $0.60 million.

When did Aeterna Zentaris' stock split?

Aeterna Zentaris's stock reverse split on the morning of Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Aeterna Zentaris own?
What is Aeterna Zentaris' stock symbol?

Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

Who are Aeterna Zentaris' major shareholders?

Aeterna Zentaris' stock is owned by a number of retail and institutional investors. Top institutional investors include Group One Trading L.P. (0.00%), Susquehanna International Group LLP (0.00%), Cutler Group LLC CA (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $2.71.

How much money does Aeterna Zentaris make?

Aeterna Zentaris (NASDAQ:AEZS) has a market capitalization of $13.17 million and generates $5.26 million in revenue each year. The biopharmaceutical company earns $-8,370,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis.

How can I contact Aeterna Zentaris?

Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The official website for the company is www.zentaris.com. The biopharmaceutical company can be reached via phone at (418) 652-8525, via email at ir@aezsinc.com, or via fax at 418-948-9191.

This page (NASDAQ:AEZS) was last updated on 3/20/2023 by MarketBeat.com Staff